DMAC - NASDAQ
DiaMedica Therapeutics Inc.
$5.84
+1.2%DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
At a Glance
Live Snapshotdmac
Account Payables
Last Annual Value
1.48M
3-Year CAGR
26%
5-Year CAGR
6%
10-Year CAGR
8%
DiaMedica Therapeutics Inc. Competitors Analysis of Account Payables
| Company | Account Payables | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
DiaMedica Therapeutics Inc. NASDAQ:DMAC | 1.48M | 16.8% | 23.7% | 19.4% | |
 I-Mab NASDAQ:IMAB | 0.00 | N/A | N/A | N/A | |
 Aardvark Therapeutics, Inc. Common Stock NASDAQ:AARD | 2.07M | 26.0% | N/A | N/A | |
 Candel Therapeutics, Inc. NASDAQ:CADL | 1.13M | 38.8% | -6.6% | N/A | |
1.02M | 17.0% | 9.0% | N/A | ||
 LB Pharmaceuticals Inc Common Stock NASDAQ:LBRX | 2.13M | 15.3% | N/A | N/A | |
 Humacyte, Inc. NASDAQ:HUMA | 5.40M | -5.9% | 20.9% | N/A | |
 Replimune Group, Inc. NASDAQ:REPL | 12.46M | 32.4% | 39.5% | N/A | |
 Galectin Therapeutics Inc. NASDAQ:GALT | 3.25M | -20.4% | 12.4% | 13.6% | |
 Annexon, Inc. NASDAQ:ANNX | 14.93M | 39.6% | 6.0% | N/A | |
 Genelux Corporation NASDAQ:GNLX | 0.00 | N/A | N/A | N/A |
DiaMedica Therapeutics Inc. Fair Value Envelope
Related Guides
Continue your DMAC research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.